A detailed history of Lyell Wealth Management, LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Lyell Wealth Management, LP holds 1,671 shares of ABBV stock, worth $299,443. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,671
Previous 1,671 -0.0%
Holding current value
$299,443
Previous $286,000 15.03%
% of portfolio
0.03%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$154.79 - $180.76 $9,906 - $11,568
64 Added 3.98%
1,671 $286,000
Q1 2024

May 03, 2024

BUY
$159.82 - $182.1 $3,995 - $4,552
25 Added 1.58%
1,607 $292,000
Q4 2023

Feb 02, 2024

SELL
$137.6 - $154.97 $11,283 - $12,707
-82 Reduced 4.93%
1,582 $245,000
Q3 2023

Oct 31, 2023

SELL
$133.59 - $154.65 $94,715 - $109,646
-709 Reduced 29.88%
1,664 $248,000
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $5,830 - $7,255
-44 Reduced 1.82%
2,373 $319,000
Q1 2023

May 03, 2023

BUY
$144.61 - $166.54 $8,676 - $9,992
60 Added 2.55%
2,417 $385,000
Q4 2022

Jan 24, 2023

BUY
$138.31 - $165.87 $43,429 - $52,083
314 Added 15.37%
2,357 $0
Q3 2022

Oct 24, 2022

SELL
$134.21 - $153.93 $39,457 - $45,255
-294 Reduced 12.58%
2,043 $274,000
Q2 2022

Jul 28, 2022

BUY
$137.62 - $174.96 $35,918 - $45,664
261 Added 12.57%
2,337 $358,000
Q1 2022

May 04, 2022

BUY
$131.98 - $163.75 $37,350 - $46,341
283 Added 15.78%
2,076 $336,000
Q4 2021

Feb 08, 2022

SELL
$107.43 - $135.93 $14,073 - $17,806
-131 Reduced 6.81%
1,793 $243,000
Q3 2021

Nov 10, 2021

SELL
$106.4 - $120.78 $2,872 - $3,261
-27 Reduced 1.38%
1,924 $208,000
Q2 2021

Aug 09, 2021

SELL
$105.21 - $117.21 $59,654 - $66,458
-567 Reduced 22.52%
1,951 $220,000
Q1 2021

May 07, 2021

BUY
$102.3 - $112.62 $257,591 - $283,577
2,518 New
2,518 $272,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lyell Wealth Management, LP Portfolio

Follow Lyell Wealth Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lyell Wealth Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lyell Wealth Management, LP with notifications on news.